Literature DB >> 71943

Therapy of advanced squamous carcinoma of the lung: cyclophosphamide vesus "COMB".

G P Bodey, S W Lagakos, A C Gutierrez, H E Wilson, O S Selawry.   

Abstract

The four-drug combination of cyclophosphamide, vincristine, methyl CCNU and bleomycin was compared to CTX alone in a prospective randomized trial. Only one of 20 patients treated with COMB and one of 27 patients treated with CTX achieved a partial response. CTX was associated with a significantly better survival than COMB among patients who were ambulatory at onset of therapy. Survival among non-ambulatory patients was similar with both regimens.

Entities:  

Mesh：

Substances：

Year:  1977        PMID： 71943     DOI： 10.1002/1097-0142(197703)39:3<1026::aid-cncr2820390305>3.0.co;2-p

Source DB:  PubMed          Journal:  Cancer        ISSN： 0008-543X            Impact factor:   6.860


  8 in total

1.  [Combination chemotherapy in patients with disseminated bronchogenic carcinoma (author's transl)].

Authors:  C Gropp; K Havemann; W D Gassel; F Hess; R Prignitz; M Schmidt; C P Sodomann
Journal:  Z Krebsforsch Klin Onkol Cancer Res Clin Oncol       Date:  1977-12-15

2.  Vindesine. A short review of preclinical and first clinical data.

Authors:  R W Dyke; R L Nelson; W P Brade
Journal:  Cancer Chemother Pharmacol       Date:  1979       Impact factor: 3.333

3.  Chemotherapy of non-small cell lung cancer: clinical trials at the Memorial Sloan-Kettering Cancer Center.

Authors:  R J Gralla; R E Wittes; E S Casper; D P Kelsen; E Cvitkovic; G B Magill; S E Krown; R B Golbey
Journal:  World J Surg       Date:  1981-09       Impact factor: 3.352

4.  Vindesine. A review of phase-II trials.

Authors:  R J Gralla; C T Tan; C W Young
Journal:  Cancer Chemother Pharmacol       Date:  1979       Impact factor: 3.333

Review 5.  Update in cancer chemotherapy, Part III: Lung cancer, Part 1.

Authors:  J C Wright
Journal:  J Natl Med Assoc       Date:  1985-10       Impact factor: 1.798

6.  Cisplatin, vinblastine, and bleomycin in inoperable non-small cell lung cancer.

Authors:  R Stuart-Harris; R M Fox; D Raghavan; A S Coates; D Hedley; J A Levi; R L Woods; M H Tattersall
Journal:  Thorax       Date:  1985-05       Impact factor: 9.139

Review 7.  Current options in the treatment of non-small cell lung cancer.

Authors:  D Faulds
Journal:  Drugs       Date:  1992       Impact factor: 9.546

8.  Cyclophosphamide and dimethylsulfoxide in the treatment of squamous carcinoma of the lung. Therapeutic efficacy, toxicity, and pharmacokinetics.

Authors:  J Z Fuks; M J Egorin; J Aisner; S S Ostrow; M E Klein; N R Bachur; M Colvin; P H Wiernik
Journal:  Cancer Chemother Pharmacol       Date:  1981       Impact factor: 3.333
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.